<DOC>
	<DOCNO>NCT02321930</DOCNO>
	<brief_summary>This proposal evaluate musculoskeletal ultrasound ( MSUS ) measure multi-biomarker disease activity ( MBDA ) improve patient treat tofacitinib 3 month , whether early MSUS measures/MBDA predict response therapy .</brief_summary>
	<brief_title>Musculoskeletal Ultrasound Assessment Therapeutic Response Tofacitinib Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>1 . Patient must meet 1987 ACR criterion 2 . Age &gt; 18 year age 3 . Baseline DAS28/ESR &gt; =3.2 4 . Stable concomitant DMARDs 5 . Stable prednisone &lt; 10mg equivalent 6 . Power Doppler score &gt; =10</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Musculoskeletal Ultrasound</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>biomarker</keyword>
</DOC>